bay2395840
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2019 (NCT05517746)
Timeline
Indications
Mechanism of action
- Bradykinin B1 receptorANTAGONIST
BDKRB1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05406219 | Phase 1 | Mar 6, 2023 | Bayer |
| NCT05563454 | Phase 1 | Oct 11, 2022 | Bayer |
| NCT05219812 | Phase 2 | Feb 16, 2022 | Bayer |
| NCT05517746 | Phase 1 | Dec 18, 2019 | Bayer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 4 | 4 | 2 | 2019 |
1 organizations
Page 1 / 1